Search Results - "Surendran, R. P."

Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia by Surendran, R. P., Visser, M. E., Heemelaar, S., Wang, J., Peter, J., Defesche, J. C., Kuivenhoven, J. A., Hosseini, M., Péterfy, M., Kastelein, J. J. P., Johansen, C. T., Hegele, R. A., Stroes, E. S. G., Dallinga-Thie, G. M.

“…  Surendran RP, Visser ME, Heemelaar S, Wang J, Peter J, Defesche JC, Kuivenhoven JA, Hosseini M, Péterfy M, Kastelein JJP, Johansen CT, Hegele RA, Stroes…”
Get full text

Pathophysiology of hypertriglyceridemia by Hassing, H.C., Surendran, R.P., Mooij, H.L., Stroes, E.S., Nieuwdorp, M., Dallinga-Thie, G.M.

“…The importance of triglycerides as risk factor for CVD is currently under debate. The international guidelines do not include TG into their risk calculator…”
Get full text

SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus by Hassing, H. Carlijne, Surendran, R. Preethi, Derudas, Bruno, Verrijken, An, Francque, Sven M., Mooij, Hans L., Bernelot Moens, Sophie J., Hart, Leen M.'t, Nijpels, Giel, Dekker, Jacqueline M., Williams, Kevin Jon, Stroes, Erik S. G., Van Gaal, Luc F., Staels, Bart, Nieuwdorp, Max, Dallinga‐Thie, Geesje M.

“…Objective Hepatic overexpression of sulfatase‐2 (SULF2), a heparan sulfate remodeling enzyme, strongly contributes to high triglyceride (TG) levels in obese,…”
Get full text

Mutations in LPL, AP0C2, AP0A5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia by SURENDRAN, R. P, VISSER, M. E, JOHANSEN, C. T, HEGELE, R. A, STROES, E. S. G, DALLINGA-THIE, G. M, HEEMELAAR, S, WANG, J, PETER, J, DEFESCHE, J. C, KUIVENHOVEN, J. A, HOSSEINI, M, PETERFY, M, KASTELEIN, J. J. P

Get full text